<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140272" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Primary Intraocular Lymphoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Simakurthy</surname>
            <given-names>Sriram</given-names>
          </name>
          <aff>AIIMS, NEW DELHI</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jena</surname>
            <given-names>Soumya</given-names>
          </name>
          <aff>Aravind Eye Hospital, Madurai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathy</surname>
            <given-names>Koushik</given-names>
          </name>
          <aff>ASG Eye Hospital, BT Road, Kolkata, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sriram Simakurthy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Soumya Jena declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Koushik Tripathy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140272.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Primary intraocular lymphoma is a subset of the primary central nervous system lymphoma characterized by monoclonal proliferation of lymphocytes. It is a very rare ocular neoplasm with high morbidity and mortality. This activity describes the signs useful in the evaluation and treatment of primary intraocular lymphoma. It highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of primary intraocular lymphoma.</p></list-item><list-item><p>Summarize the relevant history and clinical findings of patients with primary intraocular lymphoma.</p></list-item><list-item><p>Review the evaluation process of patients with primary intraocular lymphoma.</p></list-item><list-item><p>Outline the management and interprofessional care of patients with primary intraocular lymphoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140272&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140272">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140272.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Primary intraocular lymphoma (PIOL) is a rare ocular malignancy and is considered as a subset of primary central nervous system lymphoma (PCNSL) with ocular involvement.<xref ref-type="bibr" rid="article-140272.r1">[1]</xref>&#x000a0;It is an extranodal non-Hodgkin, diffuse large B cell lymphoma. It was earlier known as &#x0201c;malignant lymphoma of the uveal tract&#x0201d;&#x000a0;and &#x0201c;reticulum cell sarcoma,&#x0201d;&#x000a0;which was misleading, and hence, these names went out of vogue. As vitreoretinal manifestations predominate, it is also known as primary vitreoretinal lymphoma (PVRL)&#x000a0;or primary central nervous system lymphoma-ocular or ophthalmic variant (PCNSL-O)&#x000a0;in literature.<xref ref-type="bibr" rid="article-140272.r2">[2]</xref><xref ref-type="bibr" rid="article-140272.r3">[3]</xref><xref ref-type="bibr" rid="article-140272.r4">[4]</xref><xref ref-type="bibr" rid="article-140272.r5">[5]</xref></p>
        <p>Secondary intraocular lymphoma arises outside the central nervous system or eye and later metastasizes to the eye.<xref ref-type="bibr" rid="article-140272.r6">[6]</xref>&#x000a0;The lymphoma cells here predominantly involve the uveal tissue.<xref ref-type="bibr" rid="article-140272.r7">[7]</xref>&#x000a0;Primary uveal lymphoma is a less common entity involving B cell infiltration of the uveal tract and belongs to the extranodal marginal zone or mucosa-associated lymphoid tissue lymphoma.<xref ref-type="bibr" rid="article-140272.r8">[8]</xref> It is distinct from PIOL of diffuse large B cells and carries a better prognosis.<xref ref-type="bibr" rid="article-140272.r9">[9]</xref></p>
      </sec>
      <sec id="article-140272.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiopathogenesis of primary intraocular lymphoma is still not well understood.</p>
        <p><bold>Chemokine theory &#x02013;</bold> B cell chemokines such as B-lymphocyte chemoattractant (BLC) and stromal cell-derived factor-1 (SDF-1) present in retinal pigment epithelium (RPE) attract lymphoma cells from the choroidal circulation to RPE.<xref ref-type="bibr" rid="article-140272.r10">[10]</xref></p>
        <p><bold>Infection theory</bold> &#x02013; Infectious agents are known to cause lymphocyte proliferation which later turns into clonal proliferation. Epstein-Barr virus (EBV) infection of the B lymphocytes results in uncontrolled proliferation of the lymphocytes in the absence of T- suppressor lymphocytes in immunodeficiency states such as AIDS (acquired immunodeficiency syndrome).<xref ref-type="bibr" rid="article-140272.r11">[11]</xref> This is supported by the invariable presence of EBV in AIDS patients with PCNSL. However, a similar association has not been noted in immunocompetent individuals with PIOL.<xref ref-type="bibr" rid="article-140272.r12">[12]</xref> Similarly, Toxoplasma gondii DNA has been detected in B cell lymphoma cells of PIOL.<xref ref-type="bibr" rid="article-140272.r13">[13]</xref></p>
      </sec>
      <sec id="article-140272.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The exact epidemiology of PIOL is not known. Most of the available data relates to a larger group of primary central nervous system lymphoma. PCNSL accounts for 1 to 2% of all extranodal lymphomas and 3 to 5% of primary CNS&#x000a0;(central nervous system) tumors.<xref ref-type="bibr" rid="article-140272.r14">[14]</xref> It is more commonly seen in immunocompromised individuals.<xref ref-type="bibr" rid="article-140272.r15">[15]</xref>&#x000a0;However, with the advent of highly active antiretroviral therapy (HAART), its incidence among immunocompromised individuals has come down.<xref ref-type="bibr" rid="article-140272.r16">[16]</xref>&#x000a0;</p>
        <p>Primary intraocular lymphoma usually occurs in adults from the third to eighth decade of life, with a mean age of presentation in the fifth and sixth decades of life.<xref ref-type="bibr" rid="article-140272.r17">[17]</xref> Few cases have been reported in extremes of age group. In Immunocompromised individuals, PIOL occurs in younger individuals.<xref ref-type="bibr" rid="article-140272.r18">[18]</xref> There are no known racial or ethnic associations. Women are more commonly affected than men in the ratio of 2&#x000a0;to 1.<xref ref-type="bibr" rid="article-140272.r19">[19]</xref></p>
      </sec>
      <sec id="article-140272.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Most primary intraocular lymphomas originate from B lymphocytes (late germinal or post germinal center).<xref ref-type="bibr" rid="article-140272.r20">[20]</xref> Very rarely, PIOLs may have T cell origin.<xref ref-type="bibr" rid="article-140272.r21">[21]</xref> Primary CNS lymphoma originates from late germinal or post-germinal center lymphoid cells with neurotrophic localization to the central nervous system.&#x000a0;The trafficking of lymphoma cells from brain to eye and vice versa involves direct invasion of the optic nerve, presence of common venous drainage, or common integrin expression.<xref ref-type="bibr" rid="article-140272.r22">[22]</xref></p>
      </sec>
      <sec id="article-140272.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Primary intraocular lymphoma is a great masquerader and can mimic nonspecific uveitis. The delay between&#x000a0;the onset of symptoms (ocular or CNS) and a positive diagnosis usually varies from 4&#x000a0;to 40 months.<xref ref-type="bibr" rid="article-140272.r23">[23]</xref> About &#x000bc;th of patients with PCNSL will have concomitant vitreoretinal lymphoma at the time of diagnosis.<xref ref-type="bibr" rid="article-140272.r24">[24]</xref> Conversely, 56 to 90% of individuals with vitreoretinal lymphoma will develop CNS involvement over a follow-up period of 8&#x000a0;to 29 months.<xref ref-type="bibr" rid="article-140272.r25">[25]</xref>&#x000a0;At the initial presentation of PIOL, about 16 to 34% of patients tend to have central nervous system involvement.<xref ref-type="bibr" rid="article-140272.r26">[26]</xref></p>
        <p>
<bold>Ophthalmic Findings</bold>
</p>
        <p>The most common symptom is a painless blurring of vision or a complaint of floaters. The disease is bilateral in 80% of the individuals and is asymmetric in presentation.<xref ref-type="bibr" rid="article-140272.r27">[27]</xref>&#x000a0;Anterior segment findings include cells in the anterior chamber, keratic precipitates, infiltration of iris or angle, and rarely pseudohypopyon. Posterior segment findings can mimic choroiditis or vasculitis and include vitritis, which is surprisingly responsive to topical and oral steroids initially. The vitreous cells may form clumps, sheets, or strands leading to media haze. The cells in PIOL are larger than inflammatory cells. These cells do not cluster with reactive cells. They are arranged along vitreous fibrils in the form of linear opacities giving rise to the "aurora borealis "appearance of vitreous or a "string of pearls" appearance, which includes fine fibrils connecting bunches of inflammatory material.<xref ref-type="bibr" rid="article-140272.r28">[28]</xref><xref ref-type="bibr" rid="article-140272.r29">[29]</xref>&#x000a0;</p>
        <p>Creamy lesions with yellowish-orange subretinal or sub-RPE infiltrate may be seen, leading to "leopard skin pigmentation" over the lesions.<xref ref-type="bibr" rid="article-140272.r30">[30]</xref>&#x000a0;This may be&#x000a0;associated with exudative retinal detachment. Spontaneous resolution may lead to RPE atrophy and subretinal fibrosis.<xref ref-type="bibr" rid="article-140272.r31">[31]</xref>&#x000a0;Posterior synechiae formation and scleral inflammation are not frequently seen in PIOL.<xref ref-type="bibr" rid="article-140272.r17">[17]</xref> In contrast to other uveitic conditions with a similar degree of inflammation, cystoid macular edema is often absent, and vision is comparatively preserved.<xref ref-type="bibr" rid="article-140272.r32">[32]</xref> Orbital involvement in PIOL is exceptionally rare and helps in differentiating it from simulating lesions.<xref ref-type="bibr" rid="article-140272.r33">[33]</xref></p>
        <p>
<bold>Central Nervous System (CNS) Findings</bold>
<bold>&#x000a0;</bold>
</p>
        <p>The new onset of seizures indicates CNS involvement in a case of PIOL.<xref ref-type="bibr" rid="article-140272.r34">[34]</xref> Symptoms can be either focal or diffuse. The most common focal symptoms include hemiparesis (51%) and cerebellar ataxia (23 %).<xref ref-type="bibr" rid="article-140272.r24">[24]</xref> Involvement of the frontal lobe leads to behavioral changes and cognitive impairment.<xref ref-type="bibr" rid="article-140272.r35">[35]</xref></p>
      </sec>
      <sec id="article-140272.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <list list-type="order">
          <list-item>
            <p>
<bold>Imaging</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Biopsy &#x00026; analysis</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Blood tests</bold>
</p>
          </list-item>
        </list>
        <table-wrap id="article-140272.table0" position="float" orientation="portrait">
          <table style="height: 140px; width: 885px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 69px;">
                <td style="width: 276px; height: 69px;" rowspan="1" colspan="1">Imaging</td>
                <td style="width: 520px; height: 69px;" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Optical coherence tomography (OCT)</p></list-item><list-item><p>Fundus fluorescein angiography (FFA)</p></list-item><list-item><p>Indocyanine green angiography (ICGA)</p></list-item><list-item><p>Fundus autofluorescence (FAF)</p></list-item><list-item><p>Ultrasonography (USG)</p></list-item><list-item><p>Neuroimaging</p></list-item></list>
</td>
              </tr>
              <tr style="height: 87px;">
                <td style="width: 276px; height: 87px;" rowspan="1" colspan="1">Biopsy and analysis</td>
                <td style="width: 520px; height: 87px;" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Histopathology</p></list-item><list-item><p>Immunohistochemistry</p></list-item><list-item><p>Cytokine analysis</p></list-item><list-item><p>Polymerase chain reaction</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 276px; height: 13px;" rowspan="1" colspan="1">Blood tests</td>
                <td style="width: 520px; height: 13px;" rowspan="1" colspan="1">To rule out common uveitic conditions and other masquerades</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>I. Imaging</bold>
</p>
        <list list-type="order">
          <list-item>
            <p><bold>Optical coherence tomography (OCT):</bold> It is helpful to demonstrate or analyze lesions at the posterior pole. Findings include nodular hyperreflective lesions in the retinal pigment epithelial layer corresponding to subretinal and sub-retinal&#x000a0;pigment epithelium (RPE) lymphoma deposits&#x000a0;(<bold>Figure 1</bold>).<xref ref-type="bibr" rid="article-140272.r36">[36]</xref> It is also useful to confirm the absence of cystoid macular edema.<xref ref-type="bibr" rid="article-140272.r32">[32]</xref>&#x000a0;The images are usually difficult to capture as the ocular media is usually hazy due to vitreous involvement.</p>
          </list-item>
          <list-item>
            <p><bold>Fundus Fluorescein angiography (FFA): </bold>Findings in FFA include small hypofluorescent lesions in the early and late phase corresponding to infiltrates masking the choroidal fluorescence,&#x000a0;with late staining at the level of RPE in another series.<xref ref-type="bibr" rid="article-140272.r37">[37]</xref> other findings include punctate hyperfluorescent window defects, vasculitis, and very rarely petaloid leak at the macula.<xref ref-type="bibr" rid="article-140272.r32">[32]</xref><xref ref-type="bibr" rid="article-140272.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Indocyanine green angiography (ICGA):</bold> It shows small hypofluorescent lesions in the early phase, which become less apparent in late phases. The hypofluorescent lesions are more numerous in FFA compared to ICGA.<xref ref-type="bibr" rid="article-140272.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Fundus Autofluorescence (FAF):</bold>&#x000a0;Sub-RPE pigment clumps&#x000a0;that give rise to "leopard spotting" appearance are hyperautofluorescent, whereas white lesions above the RPE are hypoautofluorescent.<xref ref-type="bibr" rid="article-140272.r21">[21]</xref> Granularity on FAF is noted in cases with active lymphoma.<xref ref-type="bibr" rid="article-140272.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Ocular ultrasound:</bold> There are no definitive findings of PIOL on ocular ultrasonography. The most common ultrasound findings in the case of PIOL include vitreous echoes, elevated chorioretinal lesions, and retinal detachment.<xref ref-type="bibr" rid="article-140272.r39">[39]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>&#x000a0;Neuroimaging: </bold>Computed tomography (CT) and magnetic resonance imaging (MRI) imaging of the brain show unifocal or multifocal periventricular, homogenously contrast-enhancing lesions.<xref ref-type="bibr" rid="article-140272.r40">[40]</xref><xref ref-type="bibr" rid="article-140272.r41">[41]</xref>&#x000a0;In CT imaging, the lesions are isodense or hyperdense, while in MRI, lesions are hyperintense on T1 imaging and iso-hyperintense on T2 imaging.<xref ref-type="bibr" rid="article-140272.r42">[42]</xref></p>
          </list-item>
        </list>
        <p>
<bold>II. Biopsy and Analysis</bold>
</p>
        <p>The definitive diagnosis depends on the demonstration of the malignant lymphoma cells in the ocular specimens (vitreous, aqueous, chorioretinal biopsy) or the cerebrospinal fluid (CSF).<xref ref-type="bibr" rid="article-140272.r4">[4]</xref> Typically lymphoma cells are present between RPE and Bruch's membrane; however, the lymphoma cells invade the vitreous, and hence vitreous sampling also helps in evaluation. A chorioretinal biopsy is often indicated if there is an absence of anterior chamber or vitreous cavity inflammation, the presence of a fovea threatening lesion that is non-responsive to treatment, infection with equivocal results on prior testing, or in cases with a strong suspicion of neoplasm.<xref ref-type="bibr" rid="article-140272.r43">[43]</xref> Multiple biopsies may sometimes be needed to reach a definitive pathological diagnosis. Uveal biopsies are often nondiagnostic.</p>
        <p>
<bold>Ocular Biopsy</bold>
</p>
        <p><bold>Technique:</bold>&#x000a0;Techniques of ocular biopsy include fine-needle aspiration of vitreous via pars plana (21G to 25G), pars plana vitrectomy, transscleral biopsy for subretinal lesions, anterior chamber tap, and enucleation. Vitrectomy has added advantage of clearing vitreous debris, maximizing sample collection, and access to subretinal space, although there is a risk of extension of lymphoma through the sclerotomy site to peribulbar space.<xref ref-type="bibr" rid="article-140272.r44">[44]</xref><xref ref-type="bibr" rid="article-140272.r45">[45]</xref> In cases of a painful blind eye, a diagnostic enucleation may be performed.<xref ref-type="bibr" rid="article-140272.r46">[46]</xref></p>
        <p>Techniques to increase the diagnostic yield include</p>
        <list list-type="bullet">
          <list-item>
            <p>Any corticosteroid use should be discontinued for at least two weeks before the biopsy.<xref ref-type="bibr" rid="article-140272.r47">[47]</xref></p>
          </list-item>
          <list-item>
            <p>Precautions during vitrectomy include the use of large-bore cutters and a low cut rate to reduce the shearing of cells.</p>
          </list-item>
          <list-item>
            <p>Collect undiluted fresh vitreous with infusion off.</p>
          </list-item>
          <list-item>
            <p>Since lymphoma cells undergo morphological degeneration within 60 minutes, the sample should be transported to the laboratory quickly.</p>
          </list-item>
          <list-item>
            <p>Fixation of the sample in HOPE (HEPES-glutamic acid buffer-mediated Organic solvent Protection Effect) solution may increase the yield.<xref ref-type="bibr" rid="article-140272.r48">[48]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Cerebrospinal Fluid (CSF) and Brain Biopsy</bold>
</p>
        <p>A lumbar puncture can be done to obtain CSF in cases with suspected PCNSL. In cases with a positive yield on CSF and if an intraocular lesion suspicious of PIOL is present, the need for ocular tissue biopsy is less important unless the intraocular process does not respond to the treatment initiated.<xref ref-type="bibr" rid="article-140272.r43">[43]</xref> Stereotactic brain biopsy is done in patients with negative CSF cytology and suspicious brain lesions on imaging.<xref ref-type="bibr" rid="article-140272.r49">[49]</xref></p>
        <p>
<bold>Analysis</bold>
</p>
        <list list-type="order">
          <list-item>
            <p><bold><bold>Histopathology:&#x000a0;</bold></bold>Histopathological analysis reveals a monoclonal population of large B cells with scanty cytoplasm, high nuclear: cytoplasmic ratio, hypersegmented round, oval, or clover-shaped nuclei with coarse chromatin pattern, and prominent or multiple nucleoli (<bold>Figure 2</bold>).<xref ref-type="bibr" rid="article-140272.r26">[26]</xref><xref ref-type="bibr" rid="article-140272.r45">[45]</xref>&#x000a0;Cytological evaluation has a high positive predictive value of 99 &#x02013; 100% and a negative predictive value of 61 to 81%.<xref ref-type="bibr" rid="article-140272.r50">[50]</xref><xref ref-type="bibr" rid="article-140272.r51">[51]</xref>&#x000a0;Challenges in histopathological analysis of specimens include the presence of a sparse number of cells, confounding features such as T lymphocytes, necrotic cells, and fibrin.<xref ref-type="bibr" rid="article-140272.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Immunohistochemistry and flow cytometry: </bold>The presence of a monoclonal population of a single immunophenotype supports the histopathological diagnosis. Most cases of PIOL are monoclonal B cell lymphomas and stain positively for B cell markers like CD19, CD20, CD 22, and germinal center markers such as BCL 6 and CD 10.<xref ref-type="bibr" rid="article-140272.r52">[52]</xref><xref ref-type="bibr" rid="article-140272.r53">[53]</xref> Reactive inflammatory cells tend to be T cells and express CD 3 and CD 5.<xref ref-type="bibr" rid="article-140272.r25">[25]</xref> Hence in a rare case of T cell PIOL, the distinction between inflammation and tumor is mainly based on morphology and demonstration of monoclonality.<xref ref-type="bibr" rid="article-140272.r54">[54]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Cytokines</bold>: B cells secrete high amounts of interleukin (IL) IL-10, an immunosuppressive cytokine.<xref ref-type="bibr" rid="article-140272.r55">[55]</xref><xref ref-type="bibr" rid="article-140272.r56">[56]</xref>&#x000a0;On&#x000a0;the other hand, in uveitis, the vitreous is rich in IL-6, a pro-inflammatory cytokine.<xref ref-type="bibr" rid="article-140272.r56">[56]</xref> Intravitreal IL-10: IL-6 ratio&#x0003e;1 has 75% sensitivity of distinguishing PIOL from uveitis.<xref ref-type="bibr" rid="article-140272.r57">[57]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Polymerase chain reaction (PCR):</bold> In cases of PIOL, monoclonality of the B cell population can be detected using framework regions (FR)- FR2, FR3, and complementarity determining regions 3 (CDR3) primers.<xref ref-type="bibr" rid="article-140272.r58">[58]</xref>&#x000a0;Monoclonality&#x000a0;of rare T cell PIOL can be detected through T-cell receptor (TCR) gene rearrangements.<xref ref-type="bibr" rid="article-140272.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>Given the paucity of vitreous available for testing, the histopathological analysis gets precedence, and the supernatant sample can be sent for cytokine analysis.<xref ref-type="bibr" rid="article-140272.r56">[56]</xref>&#x000a0;The sample can then be sent for immunohistochemistry/flow cytometry and PCR analysis, depending on the available sample amount.</p>
        <p><bold>III. Blood tests:</bold> These are basically done to rule out infective causes of uveitis such as syphilis, tuberculosis, herpes, toxoplasmosis, HIV (human immunodeficiency virus) status; inflammatory disorders such as sarcoidosis, Vogt Koyanagi Harada disease, Beh&#x000e7;et, and also to look at side-effects of systemic chemotherapy.</p>
      </sec>
      <sec id="article-140272.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment goals include controlling the local disease along with preventing CNS dissemination. Treatment modalities include intravitreal injections, chemotherapy, and radiotherapy, used alone or in combination. Chemotherapy is considered the first-line therapy for PCNSL.<xref ref-type="bibr" rid="article-140272.r59">[59]</xref> International PCNSL collaborative group recommends systemic therapy for PIOL with CNS involvement and local therapy for disease localized to the eye.<xref ref-type="bibr" rid="article-140272.r28">[28]</xref> Therapies commonly used in systemic lymphomas are not commonly successful in PCNSL and PIOL.</p>
        <table-wrap id="article-140272.table1" position="float" orientation="portrait">
          <table style="width: 675px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 126.656px;" rowspan="1" colspan="1">
<bold>Local Therapy</bold>
</td>
                <td style="width: 479.344px;" rowspan="1" colspan="1">Intravitreal chemotherapy, Radiation, Vitrectomy</td>
              </tr>
              <tr>
                <td style="width: 126.656px;" rowspan="1" colspan="1">
<bold>Systemic Therapy</bold>
</td>
                <td style="width: 479.344px;" rowspan="1" colspan="1">Chemotherapy, Chemoradiation</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p><bold>Local Therapy</bold>&#x000a0;</p>
        <p>
<bold>Intravitreal Methotrexate (MTX)</bold>
</p>
        <p><bold>Dose:</bold> 0.4 mg in 0.1 ml<xref ref-type="bibr" rid="article-140272.r60">[60]</xref></p>
        <p>
<bold>Indications: </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Unilateral/Bilateral PIOL</p>
          </list-item>
          <list-item>
            <p>In combination with systemic chemotherapy for PVRL with CNS involvement</p>
          </list-item>
          <list-item>
            <p>Relapsed PIOL</p>
          </list-item>
          <list-item>
            <p>Ocular relapse of PCNSL</p>
          </list-item>
        </list>
        <p>The therapeutic dose of intravitreal MTX is maintained in the vitreous for five days.<xref ref-type="bibr" rid="article-140272.r61">[61]</xref> The most common administration scheme of intravitreal methotrexate is twice weekly for four weeks in the induction phase, weekly for eight weeks in the consolidation phase, and monthly for another nine months in the maintenance phase with a total of 25 injections.<xref ref-type="bibr" rid="article-140272.r60">[60]</xref> A mean of 6.4 injections was needed to reach remission, with 95% of cases receiving 13 injections or less.<xref ref-type="bibr" rid="article-140272.r60">[60]</xref></p>
        <p>The common complications of intravitreal MTX include cataracts, corneal epitheliopathy and maculopathy, limbal stem cell damage, optic atrophy, and sterile endophthalmitis.<xref ref-type="bibr" rid="article-140272.r53">[53]</xref> An aqueous paracentesis should be done to avoid subconjunctival extravasation, which can lead to pain, irritation, and corneal epitheliopathy.<xref ref-type="bibr" rid="article-140272.r62">[62]</xref></p>
        <p>
<bold>Intravitreal Rituximab</bold>
</p>
        <p><bold>Dose: </bold>1 mg in 0.1 ml<xref ref-type="bibr" rid="article-140272.r63">[63]</xref></p>
        <p>It is an anti-CD20 monoclonal antibody, given as an intravitreal injection. There is a lack of standardization of treatment schedules varying from a single injection to multiple injections at variable intervals.<xref ref-type="bibr" rid="article-140272.r64">[64]</xref> It is usually given&#x000a0;as four-weekly intervals.<xref ref-type="bibr" rid="article-140272.r64">[64]</xref><xref ref-type="bibr" rid="article-140272.r65">[65]</xref>&#x000a0;The primary response is usually good, but subsequent relapses may require intravitreal methotrexate and radiation.<xref ref-type="bibr" rid="article-140272.r63">[63]</xref>&#x000a0;Complications related to intravitreal injection of rituximab include cataract formation, increased intraocular pressure, granulomatous anterior uveitis, vitreous hemorrhage, and retinal detachment.<xref ref-type="bibr" rid="article-140272.r64">[64]</xref>&#x000a0;</p>
        <p>
<bold>Radiation Therapy</bold>
</p>
        <p>External beam radiotherapy is given to patients with PIOL without CNS involvement.<xref ref-type="bibr" rid="article-140272.r28">[28]</xref>&#x000a0;Traditionally given in the dose of 54Gy, but due to increased risk of radiation retinopathy, the dose has been reduced to 35&#x000a0;to 40 Gy in approximately 15 fractions of 2Gy each, from opposed lateral beams to include both the eyes.<xref ref-type="bibr" rid="article-140272.r19">[19]</xref><xref ref-type="bibr" rid="article-140272.r66">[66]</xref> &#x000a0;</p>
        <p>Whole-brain radiotherapy is added with ocular radiotherapy in cases with CNS dissemination and who do not respond to systemic chemotherapy or cannot tolerate aggressive therapies.<xref ref-type="bibr" rid="article-140272.r66">[66]</xref>&#x000a0;High dose low fractionation CNS irradiation can cause neurotoxicity, which can present in the form of depression.<xref ref-type="bibr" rid="article-140272.r67">[67]</xref>&#x000a0;The ocular side effects of external beam radiotherapy include dermatitis, punctate keratopathy, radiation retinopathy, cataract, optic neuropathy, and dry eye syndrome.<xref ref-type="bibr" rid="article-140272.r6">[6]</xref></p>
        <p>
<bold>Vitrectomy</bold>
</p>
        <p>In cases with significant cellular load, this can be considered as an adjunct therapy for debulking.<xref ref-type="bibr" rid="article-140272.r43">[43]</xref> This is often combined with intravitreal chemotherapy.&#x000a0;</p>
        <p>
<bold>Systemic Therapy</bold>
</p>
        <p>
<bold>Chemotherapy</bold>
</p>
        <p>Chemotherapy is the mainstay of the treatment - usually used in combination with radiation therapy or can also be used alone as primary therapy. The main barrier to systemic chemotherapy is penetration via the blood-brain barrier and blood-ocular barrier. Methotrexate and Cytosine arabinoside penetrate the blood-ocular barrier and are commonly used.</p>
        <p><bold>Route</bold> &#x02013; Intravenous, Intrathecal<bold/></p>
        <p>
<bold>Methotrexate (MTX)</bold>
</p>
        <p>High-dose methotrexate can penetrate the blood-brain barrier, with a complete response rate of 50 to 80%,<xref ref-type="bibr" rid="article-140272.r68">[68]</xref>&#x000a0;and is usually included in all chemotherapeutic regimens. It is given in the dose of 8 g/m^2 intravenously. In the induction phase, it is given every 14 days until complete response, every 14 days for two doses in the consolidation phase, and every 28 days for 11 months in the maintenance phase.<xref ref-type="bibr" rid="article-140272.r69">[69]</xref>&#x000a0;Intrathecal methotrexate is given in a dose of 12 mg or 6 mg by Ommaya reservoir administered once per cycle.<xref ref-type="bibr" rid="article-140272.r70">[70]</xref></p>
        <p>Systemic MTX can cause ocular complications like periorbital edema, increased lacrimation, photophobia, blepharitis, conjunctival hyperemia, and photophobia.<xref ref-type="bibr" rid="article-140272.r53">[53]</xref> Intrathecal methotrexate plays a role in cases with PIOL with CNS involvement.<xref ref-type="bibr" rid="article-140272.r71">[71]</xref></p>
        <p>
<bold>Cytosine Arabinoside (Ara-C)</bold>
</p>
        <p>Cytosine Arabinoside, also used as a chemotherapeutic agent, can penetrate the ocular blood barrier.<xref ref-type="bibr" rid="article-140272.r72">[72]</xref> High-dose Cytosine arabinoside (Ara-C) is given in the dose of 2&#x000a0;to 3 g/m^2 for three months for six cycles.<xref ref-type="bibr" rid="article-140272.r73">[73]</xref> Intrathecal cytarabine is given in a dosage of 100 mg once per cycle.<xref ref-type="bibr" rid="article-140272.r70">[70]</xref> Ocular complications of Ara-C include ocular irritation, conjunctivitis, and keratitis.&#x000a0;</p>
        <p>
<bold>Rituximab</bold>
</p>
        <p>Intravenous rituximab is usually given along with methotrexate in cases with relapse/ recurrences of PVRL in the dose of 375mg/sqm.<xref ref-type="bibr" rid="article-140272.r63">[63]</xref><xref ref-type="bibr" rid="article-140272.r70">[70]</xref><bold/></p>
        <p>
<bold>Combination Chemotherapy</bold>
</p>
        <p>A combination of MTX and Ara-C was used in patients with both ocular and CNS disease by Valluri et al.<xref ref-type="bibr" rid="article-140272.r74">[74]</xref>&#x000a0;Both ocular and CNS disease resolved with remission of at least 24 months.<xref ref-type="bibr" rid="article-140272.r53">[53]</xref>&#x000a0;MATRix therapy, which is a combination of MTX, cytarabine, thiotepa, and rituximab, has been tried in patients &#x0003c; 70 years of age with good response.<xref ref-type="bibr" rid="article-140272.r75">[75]</xref> It has shown a complete remission rate of 50% compared to groups treated with MTX and cytarabine, where remission rate was 23%, and the group treated with MTX, cytarabine, and rituximab, where remission rate was 30%.<xref ref-type="bibr" rid="article-140272.r75">[75]</xref></p>
        <p>Autologous stem cell transplantation is done in cases of refractory or recurrent PCNSL and PIOL after a course of intensive chemotherapy to rescue from systemic side effects of high-dose chemotherapy.<xref ref-type="bibr" rid="article-140272.r76">[76]</xref></p>
        <p>
<bold>Drugs Under Ongoing Trials</bold>
<bold>&#x000a0;</bold>
</p>
        <p>
<bold>Pomalidomide</bold>
</p>
        <p>It's a thalidomide-based agent, usually used for systemic diffuse large B cell lymphoma with better penetration to CNS.&#x000a0;It has been tried along with dexamethasone systemically for recurrent or refractory CNS and vitreoretinal lymphoma with promising results.&#x000a0;The dose-escalation schedule of pomalidomide that followed was 3,5,7,10 mg orally daily for 21 days every 28 days and dexamethasone 40 mg every week.<xref ref-type="bibr" rid="article-140272.r77">[77]</xref></p>
        <p>
<bold>Ibrutinib</bold>
</p>
        <p>It is an orally administered agent with significant penetration of the blood ocular/CNS barrier.<xref ref-type="bibr" rid="article-140272.r70">[70]</xref>&#x000a0;It acts by inhibiting Bruton tyrosine kinase and HCK tyrosine kinase protein, both of which are upregulated by MYD88 L265P mutation.<xref ref-type="bibr" rid="article-140272.r53">[53]</xref> The presence of this particular mutation is responsible for potential sensitivity to Ibrutinib. It has been tried in the dosage of 560 mg orally once daily for 28 days until disease progression, or unacceptable toxicity occurred.<xref ref-type="bibr" rid="article-140272.r78">[78]</xref> It is usually reserved for patients with relapse or recurrences of PCNSL and PVRL. Ibrutinib with high-dose systemic steroids can lead to invasive fungal and pneumocystis infections.<xref ref-type="bibr" rid="article-140272.r79">[79]</xref></p>
        <p>
<bold>Lenalidomide plus Rituximab</bold>
</p>
        <p>Lenalidomide and rituximab combination has shown promising results in recurrent/ relapsing PCNSL.<xref ref-type="bibr" rid="article-140272.r80">[80]</xref>&#x000a0;The regimen includes eight 28-day cycles of induction phase (lenalidomide 20 mg/day, days 1&#x000a0;through 21 for cycle one followed by 25 mg/day, days 1&#x000a0;through 21 for subsequent cycles in combination with intravenous rituximab 375 mg/m^2 ), and twelve 28-day cycles of maintenance phase (lenalidomide alone in the dose of 10 mg/day, days 1&#x000a0;through 21).<xref ref-type="bibr" rid="article-140272.r80">[80]</xref></p>
        <p>
<bold>Chemoradiation</bold>
</p>
        <p>Combining chemotherapy with radiation can be used as primary therapy or as salvage therapy in PIOL.<xref ref-type="bibr" rid="article-140272.r81">[81]</xref> Intra-thecal chemotherapy can also be combined with radiation.<xref ref-type="bibr" rid="article-140272.r82">[82]</xref>&#x000a0;Multimodal therapy leads to better disease control with delayed cognitive neurotoxicity.<xref ref-type="bibr" rid="article-140272.r83">[83]</xref>&#x000a0;Rituximab and methotrexate-based systemic chemotherapy along with intravitreal methotrexate and low dose brain irradiation (23.4Gy) had shown disease-free survival of up to 25 months.<xref ref-type="bibr" rid="article-140272.r84">[84]</xref></p>
      </sec>
      <sec id="article-140272.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Diagnosis of PIOL is very challenging as various infectious and non-infectious diseases can mimic the clinical condition. Various differentials include</p>
        <p>
<bold>Inflammatory Diseases</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Posterior uveitis/panuveitis</p>
          </list-item>
          <list-item>
            <p>Intermediate uveitis<xref ref-type="bibr" rid="article-140272.r85">[85]</xref></p>
          </list-item>
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Vogt Koyanagi Harada disease</p>
          </list-item>
          <list-item>
            <p>Beh&#x000e7;et disease</p>
          </list-item>
          <list-item>
            <p>Multifocal choroiditis<xref ref-type="bibr" rid="article-140272.r86">[86]</xref></p>
          </list-item>
          <list-item>
            <p>Multiple evanescent white dot syndrome</p>
          </list-item>
          <list-item>
            <p>Acute posterior multifocal placoid pigment epitheliopathy</p>
          </list-item>
          <list-item>
            <p>Birdshot choroidopathy</p>
          </list-item>
          <list-item>
            <p>Serpiginous chorioretinopathy</p>
          </list-item>
          <list-item>
            <p>Frosted branch angiitis</p>
          </list-item>
        </list>
        <p>
<bold>Infectious Diseases</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tubercular uveitis</p>
          </list-item>
          <list-item>
            <p>Endophthalmitis<xref ref-type="bibr" rid="article-140272.r87">[87]</xref></p>
          </list-item>
          <list-item>
            <p>Syphilis<xref ref-type="bibr" rid="article-140272.r88">[88]</xref></p>
          </list-item>
          <list-item>
            <p>Toxoplasmosis<xref ref-type="bibr" rid="article-140272.r89">[89]</xref></p>
          </list-item>
          <list-item>
            <p>Acute retinal necrosis<xref ref-type="bibr" rid="article-140272.r90">[90]</xref></p>
          </list-item>
          <list-item>
            <p>Herpetic uveitis</p>
          </list-item>
        </list>
        <p>
<bold>Neoplasms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amelanotic melanoma</p>
          </list-item>
          <list-item>
            <p>Metastatic cancers</p>
          </list-item>
        </list>
        <p>In a study, the most useful signs to differentiate lymphoma from simulating conditions listed above were &#x02013; better vision, less anterior chamber flare, less posterior synechiae, and less optic disc swelling, retinal vasculitis, or disc involvement.<xref ref-type="bibr" rid="article-140272.r32">[32]</xref></p>
      </sec>
      <sec id="article-140272.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>The treatment plan for the management of PIOL is varied, and no common consensus is available. The protocol suggested by Pulido et al. for treatment has been discussed in the following figures (<bold>Figures 3, 4, and 5</bold>).<xref ref-type="bibr" rid="article-140272.r70">[70]</xref></p>
      </sec>
      <sec id="article-140272.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>PIOL with CNS involvement has a poor ocular prognosis due to the intrinsic aggressive nature of the disease. In PIOL, the mortality rate ranges from 9 to 81% in a follow-up period from 12 to 35 months.<xref ref-type="bibr" rid="article-140272.r26">[26]</xref>&#x000a0;According to Hormigo et al., the survival advantage if PIOL was diagnosed before CNS involvement was found to be 60 months versus 35 months if it was found later.<xref ref-type="bibr" rid="article-140272.r91">[91]</xref></p>
        <p>The IELSG score used for PCNSL prognostication is valid only for PVRL with CNS involvement.<xref ref-type="bibr" rid="article-140272.r75">[75]</xref> Primary CNS lymphoma has a poor five-year survival rate of 30%.<xref ref-type="bibr" rid="article-140272.r92">[92]</xref>&#x000a0;The median survival in patients with PCNSL, who are treated with radiotherapy alone or chemoradiation, can go up to 10 to 16 months.<xref ref-type="bibr" rid="article-140272.r93">[93]</xref> With methotrexate-based chemotherapy or ifosfamide or trofosfamide, the medial survival rate can go up to 30 months.<xref ref-type="bibr" rid="article-140272.r93">[93]</xref><xref ref-type="bibr" rid="article-140272.r94">[94]</xref></p>
        <p>In a study by Grimm et al., the patients after receiving a mix of therapies had a median survival of 31 months and median progression-free survival of 18 months, with ocular therapy causing no improvement in chances of survival.<xref ref-type="bibr" rid="article-140272.r95">[95]</xref></p>
      </sec>
      <sec id="article-140272.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Unlike other posterior uveitides, which PIOL masquerades, if not detected and treated early, it may progress to CNS involvement with high fatality rates. The use of chemotherapeutic agents to treat the disease presents its own set of systemic and local complications such as pancytopenia, hepatic dysfunction, dry eye, cataract, and radiation retinopathy.</p>
      </sec>
      <sec id="article-140272.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients diagnosed with primary intraocular lymphoma should be informed about the risk of central nervous system involvement and its symptoms such as behavioral change, new onset of seizures, hemiparesis, and ataxia.</p>
      </sec>
      <sec id="article-140272.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to the high correlation between PIOL and PCNSL, collaboration with a neuro-oncologist, when available, enhances patient care. Baseline screening and periodic evaluation to look for PCNSL by neurologists help identify cases with high-risk mortality and early initiation of aggressive systemic chemotherapy. An ocular pathologist should be consulted before collecting any diagnostic specimens to help handle and process the specimen appropriately.</p>
      </sec>
      <sec id="article-140272.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140272&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140272">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/primary-intraocular-lymphoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=140272">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140272/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140272">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-140272.s16">
        <fig id="article-140272.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Figure 1: color fundus picture showing hazy vitreous media with multiple sub retinal yellow deposits and corresponding optical coherence tomography scan showing hyper reflective nodules in sub retinal space Contributed by Simakurthy Sriram, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oct" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140272.s17">
        <fig id="article-140272.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Figure 2: Vitreous specimen collected in syringe and histopathological examination showing uniform population of small lymphocytes Contributed by Sriram Simakurthy, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hpe" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140272.s18">
        <fig id="article-140272.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Figure 3: Management of unilateral primary vitreoretinal lymphoma (PVRL) without central nervous system (CNS) involvement; MTX=methotrexate Contributed by Soumya Jena</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screenshot__x205x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140272.s19">
        <fig id="article-140272.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Figure 4: Management of bilateral primary vitreoretinal lymphoma (PVRL) Contributed by Soumya Jena</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screenshot__x206x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140272.s20">
        <fig id="article-140272.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Figure 5: Management of vitreoretinal lymphoma (VRL) with the involvement of central nervous system (CNS) Contributed by Soumya Jena</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screenshot__x207x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-140272.s21">
        <title>References</title>
        <ref id="article-140272.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrey</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Ben-Porat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Panageas</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berkey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leibel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.</article-title>
            <source>J Clin Oncol</source>
            <year>2006</year>
            <month>Dec</month>
            <day>20</day>
            <volume>24</volume>
            <issue>36</issue>
            <fpage>5711</fpage>
            <page-range>5711-5</page-range>
            <pub-id pub-id-type="pmid">17116938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>COOPER</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>RIKER</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Malignant lymphoma of the uveal tract.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1951</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>1153</fpage>
            <page-range>1153-8</page-range>
            <pub-id pub-id-type="pmid">14857107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klingele</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Ocular reticulum cell sarcoma.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1975</year>
            <month>Jan</month>
            <volume>79</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-47</page-range>
            <pub-id pub-id-type="pmid">1089097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Narula</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Honavar</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Primary vitreoretinal lymphoma.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>180</fpage>
            <page-range>180-6</page-range>
            <pub-id pub-id-type="pmid">25971162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raval</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Binkley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Valenzuela</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peereboom</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system lymphoma - ocular variant: an interdisciplinary review on management.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>1009</fpage>
            <page-range>1009-1020</page-range>
            <pub-id pub-id-type="pmid">33762182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buggage</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Ocular manifestations of central nervous system lymphoma.</article-title>
            <source>Curr Opin Oncol</source>
            <year>2001</year>
            <month>May</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>137</fpage>
            <page-range>137-42</page-range>
            <pub-id pub-id-type="pmid">11307054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Buggage</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Intraocular lymphoma.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>411</fpage>
            <page-range>411-8</page-range>
            <pub-id pub-id-type="pmid">12441846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Foss</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Hidayat</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Cockerham</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hummel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases.</article-title>
            <source>J Pathol</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>197</volume>
            <issue>3</issue>
            <fpage>333</fpage>
            <page-range>333-40</page-range>
            <pub-id pub-id-type="pmid">12115879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Joussen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anastassiou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of a primary uveal extranodal marginal zone B-cell lymphoma by chorioretinal biopsy: case report.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2005</year>
            <month>May</month>
            <volume>243</volume>
            <issue>5</issue>
            <fpage>482</fpage>
            <page-range>482-6</page-range>
            <pub-id pub-id-type="pmid">15586289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hackett</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Buggage</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Tuaillon</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma.</article-title>
            <source>Ophthalmology</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>110</volume>
            <issue>2</issue>
            <fpage>421</fpage>
            <page-range>421-6</page-range>
            <pub-id pub-id-type="pmid">12578791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shannon-Lowe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rickinson</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Epstein-Barr virus-associated lymphomas.</article-title>
            <source>Philos Trans R Soc Lond B Biol Sci</source>
            <year>2017</year>
            <month>Oct</month>
            <day>19</day>
            <volume>372</volume>
            <issue>1732</issue>
            <pub-id pub-id-type="pmid">28893938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ongkosuwito</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Van der Lelij</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bruinenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wienesen-van Doorn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feron</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hoyng</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>de Keizer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Klok</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kijlstra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Increased presence of Epstein-Barr virus DNA in ocular fluid samples from HIV negative immunocompromised patients with uveitis.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>82</volume>
            <issue>3</issue>
            <fpage>245</fpage>
            <page-range>245-51</page-range>
            <pub-id pub-id-type="pmid">9602620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Herbort</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Tuaillon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Buggage</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Egwuagu</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Detection of Toxoplasma gondii DNA in primary intraocular B-cell lymphoma.</article-title>
            <source>Mod Pathol</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>995</fpage>
            <page-range>995-9</page-range>
            <pub-id pub-id-type="pmid">11598169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Peereboom</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system lymphoma.</article-title>
            <source>Curr Treat Options Neurol</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>347</fpage>
            <page-range>347-59</page-range>
            <pub-id pub-id-type="pmid">20842593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivero</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kuppermann</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Wiley</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Dreilinger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Acquired immunodeficiency syndrome-related intraocular B-cell lymphoma.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1999</year>
            <month>May</month>
            <volume>117</volume>
            <issue>5</issue>
            <fpage>616</fpage>
            <page-range>616-22</page-range>
            <pub-id pub-id-type="pmid">10326958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldberg</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Smithen</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Angelilli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated retinopathy in the HAART era.</article-title>
            <source>Retina</source>
            <year>2005</year>
            <season>Jul-Aug</season>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>633</fpage>
            <page-range>633-49; quiz 682-3</page-range>
            <pub-id pub-id-type="pmid">16077362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cassoux</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Merle-Beral</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bodaghi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mil&#x000e9;a</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fardeau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reux</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Xuan</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>LeHoang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Ocular and central nervous system lymphoma: clinical features and diagnosis.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <page-range>243-50</page-range>
            <pub-id pub-id-type="pmid">11262654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajagopal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Harbour</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic testing and treatment choices in primary vitreoretinal lymphoma.</article-title>
            <source>Retina</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>435</fpage>
            <page-range>435-40</page-range>
            <pub-id pub-id-type="pmid">21336066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berenbom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davila</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Harbour</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy.</article-title>
            <source>Eye (Lond)</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>1198</fpage>
            <page-range>1198-201</page-range>
            <pub-id pub-id-type="pmid">16732210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Char</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Ljung</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Desch&#x000ea;nes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Intraocular lymphoma: immunological and cytological analysis.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1988</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>12</issue>
            <fpage>905</fpage>
            <page-range>905-11</page-range>
            <pub-id pub-id-type="pmid">3067746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhat</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Jakobiec</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Papaliodis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sobrin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Primary T-cell lymphoma of the retina and cerebellum: immunophenotypic and gene rearrangement confirmation.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>148</volume>
            <issue>3</issue>
            <fpage>350</fpage>
            <page-range>350-60</page-range>
            <pub-id pub-id-type="pmid">19477711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Loddenkemper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Braziel</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Charlotte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Anagnostopoulos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>11</issue>
            <fpage>3957</fpage>
            <page-range>3957-64</page-range>
            <pub-id pub-id-type="pmid">16249468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grimm</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jahnke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Shenkier</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Siegal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Doolittle</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Batchelor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Herrlinger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Neuwelt</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Laperriere</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Omuro</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Thiel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abrey</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report.</article-title>
            <source>Ann Oncol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>1851</fpage>
            <page-range>1851-5</page-range>
            <pub-id pub-id-type="pmid">17804469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hochberg</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system lymphoma.</article-title>
            <source>J Neurosurg</source>
            <year>1988</year>
            <month>Jun</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>835</fpage>
            <page-range>835-53</page-range>
            <pub-id pub-id-type="pmid">3286832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sagoo</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Swampillai</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Plowman</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Lightman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Primary intraocular lymphoma.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2014</year>
            <season>Sep-Oct</season>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>503</fpage>
            <page-range>503-16</page-range>
            <pub-id pub-id-type="pmid">24560125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akpek</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hochberg</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Soheilian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dryja</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Jakobiec</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes.</article-title>
            <source>Ophthalmology</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>106</volume>
            <issue>9</issue>
            <fpage>1805</fpage>
            <page-range>1805-10</page-range>
            <pub-id pub-id-type="pmid">10485554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffman</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>McKelvie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Stawell</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Santamaria</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes.</article-title>
            <source>Eye (Lond)</source>
            <year>2003</year>
            <month>May</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>513</fpage>
            <page-range>513-21</page-range>
            <pub-id pub-id-type="pmid">12802353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Rubenstein</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Harbour</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Cassoux</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Touitou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Batchelor</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.</article-title>
            <source>Oncologist</source>
            <year>2011</year>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>1589</fpage>
            <page-range>1589-99</page-range>
            <pub-id pub-id-type="pmid">22045784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miserocchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giuffr&#x000e8;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cicinelli</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Querques</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Modorati</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Aurora borealis and string of pearls in vitreoretinal lymphoma: patterns of vitreous haze.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>103</volume>
            <issue>11</issue>
            <fpage>1656</fpage>
            <page-range>1656-1659</page-range>
            <pub-id pub-id-type="pmid">30709808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gass</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Grizzard</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Clarkson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Blumenkranz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wind</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Shugarman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Multifocal pigment epithelial detachments by reticulum cell sarcoma. A characteristic funduscopic picture.</article-title>
            <source>Retina</source>
            <year>1984</year>
            <season>Summer-Fall</season>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-43</page-range>
            <pub-id pub-id-type="pmid">6387833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dean</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Tumor detachments of the retinal pigment epithelium in ocular/ central nervous system lymphoma.</article-title>
            <source>Retina</source>
            <year>1996</year>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-56</page-range>
            <pub-id pub-id-type="pmid">8927810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fardeau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Merle-B&#x000e9;ral</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cassoux</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bodaghi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Davi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lehoang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2009</year>
            <month>May</month>
            <volume>147</volume>
            <issue>5</issue>
            <fpage>886</fpage>
            <page-range>886-94, 894.e1</page-range>
            <pub-id pub-id-type="pmid">19243734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayasaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Setogawa</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Intraocular lymphoma invades the optic nerve and orbit.</article-title>
            <source>Ann Ophthalmol</source>
            <year>1993</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-4</page-range>
            <pub-id pub-id-type="pmid">8427488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Jampol</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Variations in the presentation of primary intraocular lymphoma: case reports and a review.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2001</year>
            <season>May-Jun</season>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>463</fpage>
            <page-range>463-71</page-range>
            <pub-id pub-id-type="pmid">11425352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bardenstein</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Intraocular Lymphoma.</article-title>
            <source>Cancer Control</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-325</page-range>
            <pub-id pub-id-type="pmid">10761081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forooghian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Merkur</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>High-definition optical coherence tomography features of primary vitreoretinal lymphoma.</article-title>
            <source>Ophthalmic Surg Lasers Imaging</source>
            <year>2011</year>
            <month>Sep</month>
            <day>29</day>
            <volume>42 Online</volume>
            <fpage>e97</fpage>
            <page-range>e97-9</page-range>
            <pub-id pub-id-type="pmid">21956854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Csaky</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Fluorescein angiographic findings in primary intraocular lymphoma.</article-title>
            <source>Retina</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-43</page-range>
            <pub-id pub-id-type="pmid">11884876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casady</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nazemzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>Fundus autofluorescence patterns in primary intraocular lymphoma.</article-title>
            <source>Retina</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>366</fpage>
            <page-range>366-72</page-range>
            <pub-id pub-id-type="pmid">23958842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ursea</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heinemann</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Deangelis</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Ophthalmic, ultrasonographic findings in primary central nervous system lymphoma with ocular involvement.</article-title>
            <source>Retina</source>
            <year>1997</year>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-23</page-range>
            <pub-id pub-id-type="pmid">9143039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jack</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Reese</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Central nervous system lymphoma: histologic types and CT appearance.</article-title>
            <source>Radiology</source>
            <year>1988</year>
            <month>Apr</month>
            <volume>167</volume>
            <issue>1</issue>
            <fpage>211</fpage>
            <page-range>211-5</page-range>
            <pub-id pub-id-type="pmid">3279454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bessell</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hoang-Xuan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Reni</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system lymphoma: biological aspects and controversies in management.</article-title>
            <source>Eur J Cancer</source>
            <year>2007</year>
            <month>May</month>
            <volume>43</volume>
            <issue>7</issue>
            <fpage>1141</fpage>
            <page-range>1141-52</page-range>
            <pub-id pub-id-type="pmid">17433666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients.</article-title>
            <source>Neurol Sci</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>535</fpage>
            <page-range>535-542</page-range>
            <pub-id pub-id-type="pmid">30580380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bergstrom</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how?</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2014</year>
            <season>Spring</season>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-71</page-range>
            <pub-id pub-id-type="pmid">24613891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cursiefen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Holbach</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Lafaut</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Heimann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kirchner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>GO</given-names>
              </name>
            </person-group>
            <article-title>Oculocerebral non-Hodgkin's lymphoma with uveal involvement: development of an epibulbar tumor after vitrectomy.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>118</volume>
            <issue>10</issue>
            <fpage>1437</fpage>
            <page-range>1437-40</page-range>
            <pub-id pub-id-type="pmid">11030832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bechrakis</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Anastassiou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Foerster</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Heiligenhaus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pleyer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hummel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>241</volume>
            <issue>10</issue>
            <fpage>860</fpage>
            <page-range>860-70</page-range>
            <pub-id pub-id-type="pmid">14605902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trudeau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Blackstein</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Gospodarowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moffatt</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Intraocular lymphoma: report of three cases and review of the literature.</article-title>
            <source>Am J Clin Oncol</source>
            <year>1988</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-30</page-range>
            <pub-id pub-id-type="pmid">3282423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whitcup</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Buggage</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Byrnes</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>BI</given-names>
              </name>
            </person-group>
            <article-title>Improving the diagnostic yield of vitrectomy for intraocular lymphoma.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>118</volume>
            <issue>3</issue>
            <fpage>446</fpage>
            <pub-id pub-id-type="pmid">10721983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Perez-Canto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hummel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Heimann</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Assessment of HOPE fixation in vitrectomy specimens in patients with chronic bilateral uveitis (masquerade syndrome).</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>243</volume>
            <issue>9</issue>
            <fpage>847</fpage>
            <page-range>847-52</page-range>
            <pub-id pub-id-type="pmid">15909161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Update on the management of primary CNS lymphoma.</article-title>
            <source>Oncology (Williston Park)</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>228</fpage>
            <page-range>228-34; discussion 237-42, 244</page-range>
            <pub-id pub-id-type="pmid">10736810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma.</article-title>
            <source>Int J Mol Sci</source>
            <year>2011</year>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>5684</fpage>
            <page-range>5684-97</page-range>
            <pub-id pub-id-type="pmid">22016619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic testing of vitrectomy specimens.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>140</volume>
            <issue>5</issue>
            <fpage>822</fpage>
            <page-range>822-829</page-range>
            <pub-id pub-id-type="pmid">16310459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faia</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Primary intraocular lymphoma.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>133</volume>
            <issue>8</issue>
            <fpage>1228</fpage>
            <page-range>1228-32</page-range>
            <pub-id pub-id-type="pmid">19653715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Intraocular lymphoma: update on diagnosis and management.</article-title>
            <source>Cancer Control</source>
            <year>2004</year>
            <season>Sep-Oct</season>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>285</fpage>
            <page-range>285-95</page-range>
            <pub-id pub-id-type="pmid">15377987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of intraocular lymphoma.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-16</page-range>
            <pub-id pub-id-type="pmid">15209459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benjamin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Human B cell interleukin 10.</article-title>
            <source>Leuk Lymphoma</source>
            <year>1994</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>3-4</issue>
            <fpage>205</fpage>
            <page-range>205-10</page-range>
            <pub-id pub-id-type="pmid">8167552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sen</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Bodaghi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Primary intraocular lymphoma: diagnosis and differential diagnosis.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2009</year>
            <season>May-Jun</season>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>133</fpage>
            <page-range>133-41</page-range>
            <pub-id pub-id-type="pmid">19585354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolf</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Buggage</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Vitreous cytokine levels.</article-title>
            <source>Ophthalmology</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>110</volume>
            <issue>8</issue>
            <fpage>1671</fpage>
            <page-range>1671-2</page-range>
            <pub-id pub-id-type="pmid">12917196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Molecular pathology of primary intraocular lymphoma.</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>2003</year>
            <volume>101</volume>
            <fpage>275</fpage>
            <page-range>275-92</page-range>
            <pub-id pub-id-type="pmid">14971583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Brain tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Jan</month>
            <day>11</day>
            <volume>344</volume>
            <issue>2</issue>
            <fpage>114</fpage>
            <page-range>114-23</page-range>
            <pub-id pub-id-type="pmid">11150363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frenkel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hendler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Siegal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shalom</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pe'er</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>92</volume>
            <issue>3</issue>
            <fpage>383</fpage>
            <page-range>383-8</page-range>
            <pub-id pub-id-type="pmid">18303160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Smet</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Vancs</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>448</fpage>
            <page-range>448-51</page-range>
            <pub-id pub-id-type="pmid">10434868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Corneal Epithelial Toxicity after Intravitreal Methotrexate Injection for Vitreoretinal Lymphoma: Clinical and In Vitro Studies.</article-title>
            <source>J Clin Med</source>
            <year>2020</year>
            <month>Aug</month>
            <day>18</day>
            <volume>9</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">32824794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Itty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Rituximab for intraocular lymphoma.</article-title>
            <source>Retina</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-32</page-range>
            <pub-id pub-id-type="pmid">19202422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larkin</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Saboo</surname>
                <given-names>US</given-names>
              </name>
              <name>
                <surname>Comer</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Forooghian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mackensen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Merrill</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Essex</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Lake</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Vasconcelos-Santos</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Use of intravitreal rituximab for treatment of vitreoretinal lymphoma.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>98</volume>
            <issue>1</issue>
            <fpage>99</fpage>
            <page-range>99-103</page-range>
            <pub-id pub-id-type="pmid">24158837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hashida</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ohguro</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nishida</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma.</article-title>
            <source>Transl Vis Sci Technol</source>
            <year>2012</year>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">24049708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Pruitt</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Management of malignant gliomas and primary CNS lymphoma: standard of care and future directions.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>406</fpage>
            <page-range>406-15</page-range>
            <pub-id pub-id-type="pmid">22810135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system lymphomas.</article-title>
            <source>Curr Treat Options Oncol</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>309</fpage>
            <page-range>309-18</page-range>
            <pub-id pub-id-type="pmid">12057111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy.</article-title>
            <source>J Neurooncol</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>249</fpage>
            <page-range>249-57</page-range>
            <pub-id pub-id-type="pmid">10563431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soussain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Merle-B&#x000e9;ral</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reux</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fardeau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ben Othman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Binet</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lehoang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases.</article-title>
            <source>Leuk Lymphoma</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>3-4</issue>
            <fpage>339</fpage>
            <page-range>339-45</page-range>
            <pub-id pub-id-type="pmid">9031115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pulido</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Nowakowski</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Castellino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raja</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and treatment of primary vitreoretinal lymphoma: a review.</article-title>
            <source>Int J Retina Vitreous</source>
            <year>2018</year>
            <volume>4</volume>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">29760948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mason</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma.</article-title>
            <source>Ophthalmology</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>1241</fpage>
            <page-range>1241-4</page-range>
            <pub-id pub-id-type="pmid">12799254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baumann</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ritch</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Hande</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Topping</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Treatment of intraocular lymphoma with high-dose Ara-C.</article-title>
            <source>Cancer</source>
            <year>1986</year>
            <month>Apr</month>
            <day>01</day>
            <volume>57</volume>
            <issue>7</issue>
            <fpage>1273</fpage>
            <page-range>1273-5</page-range>
            <pub-id pub-id-type="pmid">2418934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strauchen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dalton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy in the management of intraocular lymphoma.</article-title>
            <source>Cancer</source>
            <year>1989</year>
            <month>May</month>
            <day>15</day>
            <volume>63</volume>
            <issue>10</issue>
            <fpage>1918</fpage>
            <page-range>1918-21</page-range>
            <pub-id pub-id-type="pmid">2702565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valluri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moorthy</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Combination treatment of intraocular lymphoma.</article-title>
            <source>Retina</source>
            <year>1995</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>125</fpage>
            <page-range>125-9</page-range>
            <pub-id pub-id-type="pmid">7624599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2020</year>
            <month>Jun</month>
            <day>20</day>
            <volume>133</volume>
            <issue>12</issue>
            <fpage>1462</fpage>
            <page-range>1462-1469</page-range>
            <pub-id pub-id-type="pmid">32452898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soussain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hoang-Xuan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taillandier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fourme</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Choquet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Witz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Casasnovas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dupriez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Souleau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Taksin</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gisselbrecht</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jaccard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Omuro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Janvier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kolb</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zini</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <collab>Soci&#x000e9;t&#x000e9; Fran&#x000e7;aise de Greffe de Mo&#x000eb;lle Osseuse-Th&#x000e9;rapie Cellulaire</collab>
            </person-group>
            <article-title>Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci&#x000e9;t&#x000e9; Fran&#x000e7;aise de Greffe de Mo&#x000eb;lle Osseuse-Th&#x000e9;rapie Cellulaire.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>May</month>
            <day>20</day>
            <volume>26</volume>
            <issue>15</issue>
            <fpage>2512</fpage>
            <page-range>2512-8</page-range>
            <pub-id pub-id-type="pmid">18413641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tun</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Atherton</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Pederson</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Reeder</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Omuro</surname>
                <given-names>AMP</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jaeckle</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Grommes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Witzig</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>Nov</month>
            <day>22</day>
            <volume>132</volume>
            <issue>21</issue>
            <fpage>2240</fpage>
            <page-range>2240-2248</page-range>
            <pub-id pub-id-type="pmid">30262659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soussain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Choquet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blonski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leclercq</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Houillier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rezai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bijou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Houot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gressin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nicolas-Virelizier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barrie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molu&#x000e7;on-Chabrot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lelez</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Clavert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coisy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leruez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Touitou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cassoux</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Daniau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ertault de la Bretonni&#x000e8;re</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El Yamani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghesqui&#x000e8;res</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hoang-Xuan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.</article-title>
            <source>Eur J Cancer</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>117</volume>
            <fpage>121</fpage>
            <page-range>121-130</page-range>
            <pub-id pub-id-type="pmid">31279304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahn</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Jerussi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Farooqui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wiestner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gea-Banacloche</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Oct</month>
            <day>13</day>
            <volume>128</volume>
            <issue>15</issue>
            <fpage>1940</fpage>
            <page-range>1940-1943</page-range>
            <pub-id pub-id-type="pmid">27503501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghesquieres</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chevrier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laadhari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chinot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Choquet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Molu&#x000e7;on-Chabrot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beauchesne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gressin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gyan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hoang-Xuan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nicolas-Virelizier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cassoux</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Touitou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Le Garff-Tavernier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Savignoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Turbiez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Soumelis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Houillier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soussain</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)&#x02020;.</article-title>
            <source>Ann Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>621</fpage>
            <page-range>621-628</page-range>
            <pub-id pub-id-type="pmid">30698644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plowman</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Montefiore</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Lightman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Multiagent chemotherapy in the salvage cure of ocular lymphoma relapsing after radiotherapy.</article-title>
            <source>Clin Oncol (R Coll Radiol)</source>
            <year>1993</year>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>315</fpage>
            <page-range>315-6</page-range>
            <pub-id pub-id-type="pmid">8305342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Char</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Ljung</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management.</article-title>
            <source>Ophthalmology</source>
            <year>1988</year>
            <month>May</month>
            <volume>95</volume>
            <issue>5</issue>
            <fpage>625</fpage>
            <page-range>625-30</page-range>
            <pub-id pub-id-type="pmid">3050698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grommes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Primary CNS Lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>20</day>
            <volume>35</volume>
            <issue>21</issue>
            <fpage>2410</fpage>
            <page-range>2410-2418</page-range>
            <pub-id pub-id-type="pmid">28640701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taoka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaburaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Araie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurokawa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy.</article-title>
            <source>Br J Haematol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>157</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-4</page-range>
            <pub-id pub-id-type="pmid">22085111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r85">
          <label>85</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Chauhan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Pars Planitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">28613790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r86">
          <label>86</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Geetha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Chorioretinitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">31869169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r87">
          <label>87</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Simakurthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Endophthalmitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">32644505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r88">
          <label>88</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Koundanya</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Syphilis Ocular Manifestations</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">32644383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r89">
          <label>89</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Retinitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">32809355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r90">
          <label>90</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bergstrom</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Acute Retinal Necrosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">29262034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hormigo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abrey</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heinemann</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment.</article-title>
            <source>Br J Haematol</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>126</volume>
            <issue>2</issue>
            <fpage>202</fpage>
            <page-range>202-8</page-range>
            <pub-id pub-id-type="pmid">15238140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YB</given-names>
              </name>
            </person-group>
            <article-title>Advances in Pathobiology of Primary Central Nervous System Lymphoma.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2017</year>
            <month>Aug</month>
            <day>20</day>
            <volume>130</volume>
            <issue>16</issue>
            <fpage>1973</fpage>
            <page-range>1973-1979</page-range>
            <pub-id pub-id-type="pmid">28776551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plotkin</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Batchelor</surname>
                <given-names>TT</given-names>
              </name>
            </person-group>
            <article-title>Primary nervous-system lymphoma.</article-title>
            <source>Lancet Oncol</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>354</fpage>
            <page-range>354-65</page-range>
            <pub-id pub-id-type="pmid">11905752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jahnke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bechrakis</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Willerding</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thiel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Korfel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.</article-title>
            <source>Ann Oncol</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>1974</fpage>
            <page-range>1974-8</page-range>
            <pub-id pub-id-type="pmid">16219622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140272.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grimm</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>McCannel</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Omuro</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Neuwelt</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Siegal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Batchelor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jahnke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shenkier</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Herrlinger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Raizer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rubenstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laperriere</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thiel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Doolittle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Iwamoto</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Abrey</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.</article-title>
            <source>Neurology</source>
            <year>2008</year>
            <month>Oct</month>
            <day>21</day>
            <volume>71</volume>
            <issue>17</issue>
            <fpage>1355</fpage>
            <page-range>1355-60</page-range>
            <pub-id pub-id-type="pmid">18936428</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
